Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04756037 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
A Phase 3 study of Contraception, sponsored by Sumitomo Pharma Switzerland.
- Active
- Registry status
- Phase 3
- Development phase
- 1,020
- Enrollment target
- 20
- Study locations
NCT04756037: Active Phase 3 study of Contraception, sponsored by Sumitomo Pharma Switzerland.
NCT04756037 is a Phase 3 study of Contraception that is active but no longer recruiting, run by Sumitomo Pharma Switzerland. The registered enrollment target is 1,020 participants, above the 440-participant average among 72 other Contraception trials with a reported enrollment target (132% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04756037, a Phase 3 study of Contraception, is active but no longer recruiting, sponsored by Sumitomo Pharma Switzerland.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,020 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
Primary Outcome
The At-Risk PI is defined as the number of on treatment pregnancies per 100 women-years of treatment. The At-Risk PI will be calculated on the basis of cycles considered at-risk of pregnancy, that is, consecutive 28-day periods without use of any other contraceptive methods and with affirmed occurrence of vaginal intercourse. On-treatment pregnancies are pregnancies with an estimated conception date between the first day of study intervention intake up to and including 7 days after the last inta
Conditions Studied
Interventions
- DRUG Relugolix Combination Therapy
Study Locations (20)
California
- Burbank - Burbank
- Canoga Park - Canoga Park
- Encinitas - Encinitas
- Gardena - Gardena
- Lancaster - Lancaster
- Long Beach - Long Beach
- Long Beach - Long Beach
- Palo Alto - Palo Alto
- Sacramento - Sacramento
- San Diego - San Diego
- San Fernando - San Fernando
- Valley Village - Valley Village
- West Covina - West Covina
Arizona
- Chandler - Chandler
- Mesa - Mesa
- Peoria - Peoria
- Phoenix - Phoenix
Colorado
- Aurora - Aurora
- Greenwood Village - Greenwood Village
Alabama
- Mobile - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2026-02 |
| Phase | Phase 3 |
What the registry record for NCT04756037 still lists
NCT04756037 is an interventional study that assigns participants to a tested intervention. Its 1,020 participants enrollment target places it among the larger protocols in the corpus, above the 440-participant average among 72 other Contraception trials with a reported enrollment target (132% higher).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which Relugolix Combination Therapy is the first listed.
NCT04756037 names 20 study sites across 4 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT04756037 about?
NCT04756037 is a clinical study titled "Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy". The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
What is the current status of trial NCT04756037?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,020 participants. The study started on 2021-03-18. Estimated completion is 2026-02.
What conditions does trial NCT04756037 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT04756037?
The interventions under investigation include: Relugolix Combination Therapy (DRUG).
Who is sponsoring clinical trial NCT04756037?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04756037 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04756037's enrollment target sits among peer trials
1,020 13th of 72 higher than 60 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.
COMPLETED · Phase 3
-
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles
COMPLETED · Phase 3
-
Study of Safety and Efficacy of an Oral Contraceptive
COMPLETED · Phase 3
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI